EpiCure Therapeutics

EpiCure Therapeutics is a biotechnology company focused on developing novel epigenetic therapies for the treatment of cancer. The company specializes in targeting histone methyltransferases, specifically the G9a and GLP enzymes, which are known to play a critical role in gene silencing and the survival of cancer cells. By utilizing potent and selective small molecule inhibitors, EpiCure aims to reprogram the epigenetic landscape of tumors to overcome drug resistance and stimulate anti-tumor immune responses. Founded on research from the Hebrew University of Jerusalem, the company is currently advancing its lead programs through pre-clinical development for both hematological malignancies and solid tumors.